34

Cyclin-Dependent Kinase 4/6 (CDK 4/6) Inhibitor Tablets/Capsules

Prescriber Criteria: Consultant Oncologist

Outpatient and Inpatient use:

1. Malignant Diseases

For the treatment of hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer:
• in combination with an aromatase inhibitor, or
• in combination with fulvestrant in women who have received prior endocrine therapy.

Duration of Approval: 1 year